Dave Fornell, ITN Editor at RSNA
Dave Fornell, ITN Editor at RSNA

Dave Fornell is the editor of Imaging Technology News magazine and Diagnostic & Interventional Cardiology magazine.

Blog | Dave Fornell, ITN Editor at RSNA | RSNA 2017| January 18, 2018 | Dave Fornell

The Top Trends at RSNA 2017

The Radiological Association of North America's (RSNA) 2017 conference will be remembered as the year artificial intelligence (AI) exploded in radiology. It was by far the biggest news and overall trend in sessions and throughout the expo floor. The key message was AI is here to help and augment radiologists, not replace them. The majority of the AI examples on the show floor run in the background of radiology IT systems to aid workflow, not offer its own clinical findings. 

Here are links to ITN’s coverage of AI at RSNA 2017:

VIDEO: Technology Report: Artificial Intelligence at RSNA 2017

 

Why AI By Any Name Is Sweet For Radiology 

VIDEO: Deep Learning is Key Technology Trend at RSNA 2017

VIDEO: How Utilization of Artificial Intelligence Will Impact Radiology

VIDEO: Examples of How Artificial Intelligence Will Improve Medical Imaging

 

Contributing editor and radiology industry expert Greg Freiherr offers insights about the key trends and technologies at RSNA in the following content:

Value in Radiology Takes on Added Depth at RSNA 2017

• RSNA 2017: Often Real Systems (Were) Not Available

 

RSNA is radiology’s premier conference of the year and is used to launch hundreds of new products and to show work-in-progress technologies. Take a tour of some of these technologies in the VIDEO “Editor's Choice of the Most Innovative New Imaging Technology at RSNA 2017.”

One of the big issues facing radiology is the potential safety regarding MRI gadolinium contrast retention. The takeaway message from attending numerous sessions and interviews on this topic is that more data is needed from large-scale, long-term patient studies. So far none of these have been established. Additionally, radiology has done a poor job of recording in the patient record what the contrast doses were or even what contrast agent was used. It is hard to conclude if there are any safety issues from incomplete or missing data and only relying on patients complaining of symptoms that may or may not be related to their MRIs. I met with two of the top RSNA MRI experts and you can watch the video interviews with Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, and Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pittsburgh Medical Center.

You can read an additional overview blog about the the current state of the gadolinium safety question, “Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety.”

Here is a link to all the key RSNA 2017 study presentations, trends and and videos

See what products vendors displayed at RSNA 2017 with listings by modality on the ITN FastPass microsite at www.rsnafastpass.com.

 

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Advances in long-length digital radiography are creating opportunities for visualization during spinal surgery, as well as pre- and post-operatively. Image courtesy of Fujifilm Medical Systems

Advances in long-length digital radiography are creating opportunities for visualization during spinal surgery, as well as pre- and post-operatively. Image courtesy of Fujifilm Medical Systems

Feature | Digital Radiography (DR) | July 19, 2019 | By Greg Freiherr
Recent advances in...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
Image by rawpixel from Pixabay

Image by rawpixel from Pixabay 

Feature | Radiology Business | July 18, 2019 | By Stefanie Manack and Judy Zakutny
Approximately 30 percent of a hospital or health system’s profit comes from imaging according, to...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...